SZEB supply drug impurity of Avatrombopag
Time:2022-12-16
Views:302
Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors
The FDA approved a supplemental New Drug Application (sNDA) for avatrombopag (Doptelet) as a treatment for adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy.
SZEB provide the impurities of Avatrombopag -related impurities,Discover all our products through our official website (https://www.ex-biotech.com/), and get in touch if you have any questions about how we can help support your work. Email:sale@ex-biotech.com.
The following are some of the impurities of Avatrombopag:
.jpg)
Wechat
Jolin
Yuzhu Lin
Ciel Wong
whatsapp